![](https://ml.globenewswire.com/media/9852d6f6-e942-4d87-a4db-81efaea9b30c/small/intra-cellular-therapies-logo.jpg)
Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar ...
Study 404 met its primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (p<0.001; effect size = 0.56). Study 404 also met its key secondary objective on the Clinical Global …